Winning ELGX Stock Forecast: Endologix Ends May With More Than 30% Gains

Our top-line performance during the first quarter reflects slightly better-than-expected growth in our OUS business driven by solid AFX growth in both the European and CAPLA markets…These accomplishments reinforce Endologix’s value proposition and our commitment to delivering the best products to physicians and patients around the globe.”

– Vaseem Mahbob, CFO of Endologix

(Source: PxHere)

Over the past 30 days, Endologix, Inc. (NASDAQ: ELGX) has been steadily climbing. Endologix, develops, produces

Read More